


Bild

4SC Share Price vs. Syndax (NASDAQ:SNDX) (Q2 2018)



- 4SC reported positive news in Q2 2018
- Management believes this is currently being overlooked by investors
 - In favour of pessimism over the potential of all Class I selective HDAC inhibitors
- Not all Class I selective HDAC inhibitors are alike
- Domatinostat
 - Class-leading safety profile & dosing flexibility
 - No dose limiting toxicities
 - Facilitates more efficacious dosing
 - No negative impact on key immune cell populations
- 4SC believes upcoming clinical data from SENSITIZE & EMERGE will differentiate domatinostat and underline its value as a combination partner with checkpoint inhibitors

7 | © 4SC AG, August 2018

Zuletzt geändert: 10:29